Skip to main content


Fig. 5 | Cancer Communications

Fig. 5

From: Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo

Fig. 5

Antitumor activity of evofosfamide in the nasopharyngeal carcinoma (NPC) xenograft tumor model. Mice bearing HNE-1 NPC xenografts were treated with evofosfamide (50 or 75 mg/kg, intraperitoneally, twice a week for 2 weeks) and/or DDP (3 mg/kg, intraperitoneally, once a week for 2 weeks). The mean tumor volumes and percent body weight change for each group are shown. * P < 0.05, ** P < 0.01

Back to article page